Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Fonseca Carriço (Guarda, Portugal), P. Caetano (Porto, Portugal), N. Melo (Porto, Portugal), H. Novais Bastos (Porto, Portugal), S. Guimarães (Porto, Portugal), C. Souto Moura (Porto, Portugal), J. Pereira (Porto, Portugal), A. Morais (Porto, Portugal). Macrolides as a potential treatment in organizing pneumonia. 1410

Member's Comments

No comment yet.

Related content which might interest you: Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Update on therapeutic strategies in community-acquired pneumonia    Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice Year: 2017 Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Potential antibiotic resistant pathogens in community-acquired pneumonia: playing it safe is anything but Source: Eur Respir J, 54 (1) 1900870; 10.1183/13993003.00870-2019 Year: 2019 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Cryptogenic organizing pneumonia – Results of treatment with clarithromycin versus corticosteroids Source: International Congress 2016 – Orphan diseases II Year: 2016 Corticosteroids for community-acquired pneumonia: a critical view of the evidence Source: Eur Respir J 2016; 48: 984-986 Year: 2016 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Rational antimicrobial therapy of slowly resolving or nonresolving pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 187s Year: 2004 Switching of antimicrobial agents in the therapy of community acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Azithromycin in treatment of atypical pneumonia in children Source: Eur Respir J 2004; 24: Suppl. 48, 716s Year: 2004 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017 Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004 The etiological agents of community-acquired pneumonia in our hospital Source: Eur Respir J 2006; 28: Suppl. 50, 735s Year: 2006 Update on preventing and managing hospital-acquired and ventilatory-associated pneumonia Source: International Congress 2019 – State of the art session: Respiratory infections Year: 2019 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011